Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients

Pharmacogenomics

Volumn 18, Issue 6, 2017, Pages 539-554

  Allegra, Sarah ^a   De Francia, Silvia ^b   Cusato, Jessica ^a   Arduino, Arianna ^a   Massano, Davide ^b   Longo, Filomena ^b   Piga, Antonio ^b   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

BCRP1; creatinine; CYP1A1; CYP1A2; CYP2D6; ferritin; iron overload; LIC; SNP; thalassemia

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEFERASIROX; FERRITIN; GLUCURONOSYLTRANSFERASE 1A1; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; ARTICLE; BCRP1 GENE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CYP1A1 GENE; CYP1A2 GENE; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; LIVER LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PEDIATRICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A1 GENE; BETA-THALASSEMIA; BLOOD; COHORT ANALYSIS; GENETICS; METABOLISM; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PRESCHOOL CHILD;

ADOLESCENT; BENZOATES; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIAZOLES;

EID: 85017401532     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0176     Document Type: Article

References (53)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N. Engl. J. Med. 353(11), 1135-1146 (2005)
2. Epar E. Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation (2007). www.pharma.us.novartis.com/
3. Nick H, Acklin P, Lattmann R et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr. Med. Chem. 10(12), 1065-1076 (2003)
4. Nick H, Wong A, Acklin P et al. ICL670A: preclinical profile. Adv. Exp. Med. Biol. 509, 185-203 (2002)
5. Waldmeier F, Bruin Gj, Glaenzel U et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab. Dispos. 38(5), 808-816 (2010)
6. Bruin Gj, Faller T, Wiegand H et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab. Dispos. 36(12), 2523-2538 (2008)
7. Galanello R, Origa R. Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev. Clin. Pharmacol. 1(2), 231-240 (2008)
8. Cappellini Md, Bejaoui M, Agaoglu L et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin. Ther. 29(5), 909-917 (2007)
9. Galanello R, Piga A, Alberti D, Rouan Mc, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to betathalassemia. J. Clin. Pharmacol. 43(6), 565-572 (2003)
10. Nisbet-Brown E, Olivieri Nf, Giardina Pj et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebocontrolled, dose-escalation trial. Lancet 361(9369), 1597-1602 (2003)
11. Taher A, Cappellini Md, Vichinsky E et al. Efficacy and safety of deferasirox doses of 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br. J. Haematol. 147(5), 752-759 (2009)
12. Chirnomas D, Smith Al, Braunstein J et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114(19), 4009-4013 (2009)
13. Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107(9), 3455-3462 (2006)
14. Lee JW, Kang HJ, Choi JY et al. Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS ONE 8(5), e64114 (2013)
15. Cusato J, Allegra S, Massano D, De Francia S, Piga A, Davolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 15(3), 263-271 (2014)
16. Cusato J, Allegra S, Francia S, Massano D, Piga A, Davolio A. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 17(6), 561-572 (2016)
17. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 101(1), 15-19 (2003)
18. Jensen PD. Evaluation of iron overload. Br. J. Haematol. 124(6), 697-711 (2004)
19. Francia S, Massano D, Piccione FM et al. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 893-894, 127-133 (2012)
20. Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169(4), 505-514 (2009)
21. Reich DE, Cargill M, Bolk S et al. Linkage disequilibrium in the human genome. Nature 411(6834), 199-204 (2001)
22. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 95(1), 26-36 (1996)
23. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 89(3), 739-761 (1997)
24. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am. Soc. Hematol. Educ 2001 (1), 47-61 (2001)
25. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102(1), 17-24 (2003)
26. Aslam N, Mettu P, Marsano-Obando LS, Martin A. Deferasirox induced liver injury in haemochromatosis. J. Coll. Physicians Surg. Pak. 20(8), 551-553 (2010)
27. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58(3), 521-590 (2006)
28. National Center for Biotechnology Information. www.ncbi.nlm.nih.gov/
29. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat. Rev. Genet. 2(12), 930-942 (2001)
30. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1 28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198(1), 1-11 (2008)
31. Cho SK, Oh ES, Park K, Park MS, Chung JY. The UGT1A3 2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet. Genomics 22(8), 598-605 (2012)
32. Riedmaier S, Klein K, Hofmann U et al. UDPglucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin. Pharmacol. Ther. 87(1), 65-73 (2010)
33. Lankisch PG, Lerch MM. Pharmacological prevention and treatment of acute pancreatitis: where are we now? Dig. Dis. 24(1-2), 148-159 (2006)
34. Schulz C, Heinemann V, Schalhorn A et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecanbased regimens in metastatic colorectal cancer. World J. Gastroenterol. 15(40), 5058-5066 (2009)
35. Hayashi Si, Watanabe J, Nakachi K, Kawajiri K. PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res. 19(17), 4797 (1991)
36. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 263(1), 131-133 (1990)
37. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 544(1), 9-41 (2003)
38. Singh S, Kumar V, Vashisht K et al. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol. Appl. Pharmacol. 257(1), 84-92 (2011)
39. B'chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 84(21-22), 779-784 (2009)
40. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125(4), 803-808 (1999)
41. Sachse C, Bhambra U, Smith G et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. 55(1), 68-76 (2003)
42. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005)
43. Engstrom K, Ameer S, Bernaudat L et al. Polymorphisms in genes encoding potential mercury transporters and urine mercury concentrations in populations exposed to mercury vapor from gold mining. Environ. Health Perspect. 121(1), 85-91 (2012)
44. Grover S, Kukreti R. A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy. Epilepsia 54(5), 936-945 (2013)
45. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27(1), 85-105 (2012)
46. Birmingham BK, Bujac SR, Elsby R et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur. J. Clin. Pharmacol. 71(3), 341-355 (2015)
47. Chu YH, Li H, Tan HS et al. Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in asian patients receiving sunitinib for renal cell carcinoma. PLoS ONE 10(8), e0134102 (2015)
48. Gotanda K, Tokumoto T, Hirota T, Fukae M, Ieiri I. Sulfasalazine disposition in a subject with 376C T (nonsense mutation) and 421C A variants in the ABCG2 gene. Br. J. Clin. Pharmacol. 80(5), 1236-1237 (2015)
49. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10(10), 1617-1624 (2009)
50. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86(2), 197-203 (2009)
51. Skoglund K, Boiso Moreno S, Jonsson JI, Vikingsson S, Carlsson B, Green H. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenet. Genomics 24(1), 52-61 (2013)
52. Warren RB, Smith Rl, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol. 128(8), 1925-1929 (2008)
53. Delord M, Rousselot P, Cayuela JM et al. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 4(10), 1582-1591 (2013)